검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 2개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||
|---|---|---|
Overview Program | Selinexor | Platinum chemotherapy: carboplatin (preferred) or cisplatin |
Overview Company | Qilu Pharmaceutical Co., Ltd. | Genelux Corporation |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | FRα | FRα |
Overview Indication | Relapsed or Refractory Multiple Myeloma | Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Cancer |
Overview Phase | PHASE_3 | PHASE_3 |
Overview Status | RECRUITING | RECRUITING |
MoA Mechanism | Targeting the nuclear export receptor | — |
MoA Biomarker | biomarker after CRS+HIPEC and a therapeutic target | biomarkers and native biologically important proteins to small molecules |
PK/PD Half-life | 8 h | — |
PK/PD Species | Mouse, Human | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro | Mouse |
PK/PD Experiment | PK | Pharmacokinetic |
Toxicology Species | Mouse, Rat, Human | Mouse |
Toxicology Animal (cat.) | Rat | Mouse |
Toxicology Major finding | Thrombocytopenia : Monitor platelet counts throughout treatment | Acute toxicity and genotoxicity assessment of environmental contaminants using Artemia salina .. The widespread presence of pharmaceuticals and industrial pollutants in aquatic environments necessitates rapid screening tools capable of detecting hazards and adverse biological effects. In this study, we selected the nauplii of Artemia salina (brine shrimp) as a model to screen for the acute toxicit… |
Clinical Primary efficacy | ORR 76.4% | ORR 87.5% |
Clinical ORR | 76.4% | 87.5% |
Clinical PFS | 13.93 | — |
Clinical OS | 36.67 | — |
Clinical Result source | ClinicalTrials.gov NCT03110562 | ClinicalTrials.gov NCT01639001 |
Clinical Data Tier / Score | S · 77 | C · 69 |
Clinical Program phase | PHASE_3 | PHASE_3 |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) | 2026년 7월 6일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 2개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||
|---|---|---|
Overview Program | Selinexor | Platinum chemotherapy: carboplatin (preferred) or cisplatin |
Overview Company | Qilu Pharmaceutical Co., Ltd. | Genelux Corporation |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | FRα | FRα |
Overview Indication | Relapsed or Refractory Multiple Myeloma | Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Cancer |
Overview Phase | PHASE_3 | PHASE_3 |
Overview Status | RECRUITING | RECRUITING |
MoA Mechanism | Targeting the nuclear export receptor | — |
MoA Biomarker | biomarker after CRS+HIPEC and a therapeutic target | biomarkers and native biologically important proteins to small molecules |
PK/PD Half-life | 8 h | — |
PK/PD Species | Mouse, Human | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro | Mouse |
PK/PD Experiment | PK | Pharmacokinetic |
Toxicology Species | Mouse, Rat, Human | Mouse |
Toxicology Animal (cat.) | Rat | Mouse |
Toxicology Major finding | Thrombocytopenia : Monitor platelet counts throughout treatment | Acute toxicity and genotoxicity assessment of environmental contaminants using Artemia salina .. The widespread presence of pharmaceuticals and industrial pollutants in aquatic environments necessitates rapid screening tools capable of detecting hazards and adverse biological effects. In this study, we selected the nauplii of Artemia salina (brine shrimp) as a model to screen for the acute toxicit… |
Clinical Primary efficacy | ORR 76.4% | ORR 87.5% |
Clinical ORR | 76.4% | 87.5% |
Clinical PFS | 13.93 | — |
Clinical OS | 36.67 | — |
Clinical Result source | ClinicalTrials.gov NCT03110562 | ClinicalTrials.gov NCT01639001 |
Clinical Data Tier / Score | S · 77 | C · 69 |
Clinical Program phase | PHASE_3 | PHASE_3 |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) | 2026년 7월 6일 (8일 전) |
추천 비교
추천 비교